Foamix Pharmaceuticals Ltd.. (FOMX) NASDAQ

$2.99 - (-)

Market Cap: $182.40M

As of 03/06/20 12:00 AM EST. Market closed.

(FOMX)

Foamix Pharmaceuticals Ltd.. (FOMX)
NASDAQ

$2.99
- (-)

Market Cap: $182.40M

As of 03/06/20 12:00 AM EST. Market closed.

Add to Portfolio

Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The ... read more

Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. read less

COMPANY PROFILE
Sector
Health Technology
Industry
Pharmaceuticals: Other
URL
Address
2 Holzman Street, HaMerkaz, Rehovot, 76704.
Sector
Health Technology
Industry
Pharmaceuticals: Other
CEO
David Domzalski
Address
2 Holzman Street, HaMerkaz, Rehovot, 76704.
PRICE CHART FOR FOAMIX PHARMACEUTICALS LTD.
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$2.99
Days Range
- - -
52 week range
$1.97 - $4.84
Volume
0
Avg. Volume (30 days)
508,891
Market Cap
$182.40M
Dividend Yield
-
P/E
-
Shares Outstanding
61,004,000
Open
-
Previous Close
$2.99
Days Range
- - -
52 week range
$1.97 - $4.84
Volume
0
Avg. Volume (30 days)
508,891
Market Cap
$182.40M
Dividend Yield
-
P/E
-
Shares Outstanding
61,004,000
FINANCIAL STATEMENTS FOR FOAMIX PHARMACEUTICALS LTD.
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR FOAMIX PHARMACEUTICALS LTD.
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Domzalski DavidCEOMar 02, 2020 Option Exercise$2.684,70512,598324,028Mar 03, 2020, 12:00 AM
Wiley Matthew T.Chief Commercial OfficerMar 02, 2020 Option Exercise$2.681,9935,336114,074Mar 03, 2020, 12:00 AM
Harsch MutyaCLO and General CounselMar 02, 2020 Option Exercise$2.681,7614,71598,232Mar 03, 2020, 12:00 AM
Wiley Matthew T.Chief Commercial OfficerDec 31, 2019 Option Exercise$3.282,5008,20070,782Jan 03, 2020, 05:24 PM
Stuart IainChief Scientific OfficerDec 31, 2019 Option Exercise$3.285141,68662,337Jan 03, 2020, 05:23 PM
Harsch MutyaCLO and General CounselDec 31, 2019 Option Exercise$3.286182,02755,172Jan 03, 2020, 05:23 PM
Domzalski DavidCEODec 31, 2019 Option Exercise$3.282,7519,023216,075Jan 03, 2020, 05:22 PM
Domzalski DavidCEONov 29, 2019 Option Exercise$2.169,84221,249218,826Dec 03, 2019, 04:32 PM
Wiley Matthew T.Chief Commercial OfficerNov 29, 2019 Option Exercise$2.169,84221,24973,282Dec 03, 2019, 04:31 PM
Harsch MutyaCLO and General CounselNov 29, 2019 Option Exercise$2.164,2849,24955,790Dec 03, 2019, 04:30 PM
Hirsch StanleyDirectorNov 04, 2019 Option Exercise$0.6232,50020,150182,500Nov 05, 2019, 04:32 PM
Hirsch StanleyDirectorOct 15, 2019 Option Exercise$0.6290,00055,800150,000Oct 17, 2019, 04:11 PM
Stuart IainChief Scientific OfficerSep 30, 2019 Option Exercise$3.076732,06662,851Oct 02, 2019, 04:20 PM
Harsch MutyaCLO and General CounselSep 30, 2019 Option Exercise$3.074631,42151,506Oct 02, 2019, 04:19 PM
Domzalski DavidCEOSep 30, 2019 Option Exercise$3.072,2566,926208,984Oct 02, 2019, 04:18 PM
Hadar IlanCFO & Country ManagerSep 10, 2019 Sale$3.5034,392120,37589,279Sep 11, 2019, 05:12 PM
Hadar IlanCFO & Country ManagerSep 09, 2019 Sale$3.509,42032,991123,671Sep 11, 2019, 05:12 PM
KAZANCHYAN ANNADirectorAug 26, 2019 Sale$3.277,04923,05037,498Aug 28, 2019, 04:36 PM
Hirsch StanleyDirectorAug 13, 2019 Option Exercise$0.6260,00037,20060,000Aug 14, 2019, 02:59 PM
KAZANCHYAN ANNADirectorJul 15, 2019 Sale$2.318081,86644,547Jul 17, 2019, 04:40 PM
Harsch MutyaCLO and General CounselJul 01, 2019 Sale$2.356391,50251,969Jul 03, 2019, 04:28 PM
Domzalski DavidCEOJul 01, 2019 Sale$2.353,3557,884211,240Jul 03, 2019, 04:27 PM
Stuart IainChief Scientific OfficerJul 01, 2019 Sale$2.359512,23563,524Jul 03, 2019, 04:26 PM
KAZANCHYAN ANNADirectorMay 20, 2019 Sale$2.6110,60027,66645,355May 20, 2019, 06:35 PM
Harsch MutyaCLO and General CounselApr 01, 2019 Sale$3.752,5199,44652,608Apr 03, 2019, 04:42 PM
Domzalski DavidCEOApr 01, 2019 Sale$3.755,09619,110214,595Apr 03, 2019, 04:40 PM
Stuart IainChief Scientific OfficerApr 01, 2019 Sale$3.751,6966,36064,475Apr 03, 2019, 12:00 AM
Wiley Matthew T.Chief Commercial OfficerMar 05, 2019 Buy$3.7613,44050,53463,440Mar 06, 2019, 04:07 PM
Schwartz AharonDirectorNov 28, 2018 Buy$3.8812,20047,373112,200Dec 06, 2018, 06:09 AM
Schwartz AharonDirectorNov 27, 2018 Buy$3.9250,000195,800100,000Dec 06, 2018, 06:09 AM
Schwartz AharonDirectorNov 26, 2018 Buy$3.8950,000194,60050,000Dec 06, 2018, 06:09 AM
Domzalski DavidCEODec 03, 2018 Sale$4.0568275146,409Dec 06, 2018, 06:06 AM
Domzalski DavidCEONov 19, 2018 Sale$3.905,03619,640146,477Nov 20, 2018, 04:07 PM
Howard Alvin DVP RegulatoryNov 19, 2018 Sale$3.903,37513,16338,414Nov 20, 2018, 04:05 PM
Stuart IainSVP R&DNov 08, 2018 Sale$4.586833,12833,602Nov 13, 2018, 06:16 AM
Domzalski DavidCEONov 08, 2018 Sale$4.582,0629,444151,513Nov 13, 2018, 06:13 AM
Howard Alvin DVP RegulatoryOct 01, 2018 Sale$5.812341,36041,789Oct 02, 2018, 05:22 PM
Elliott Russell P.VP Drug DevelopmentOct 01, 2018 Sale$5.8114282512,442Oct 02, 2018, 05:20 PM
Domzalski DavidCEOOct 01, 2018 Sale$5.816013,492153,575Oct 02, 2018, 05:18 PM
Domzalski DavidCEOSep 04, 2018 Sale$5.6767380154,176Sep 06, 2018, 04:05 PM
Domzalski DavidCEOAug 08, 2018 Sale$5.688,23846,792154,243Aug 09, 2018, 04:07 PM
Stuart IainSVP R&DAug 08, 2018 Sale$5.682,71515,42134,285Aug 09, 2018, 04:05 PM
Domzalski DavidCEOJul 02, 2018 Sale$5.106023,070162,481Jul 03, 2018, 04:09 PM
Howard Alvin DVP RegulatoryJul 02, 2018 Sale$5.102341,19342,023Jul 03, 2018, 04:07 PM
Elliott Russell P.VP Drug DevelopmentJul 02, 2018 Sale$5.1014272412,584Jul 03, 2018, 04:05 PM
Domzalski DavidCEOJun 01, 2018 Sale$5.2667352163,083Jun 04, 2018, 02:20 PM
Hirsch StanleyDirectorMay 13, 2018 Sale$5.096,16431,3696,508May 31, 2018, 04:51 PM
Hirsch StanleyDirectorMay 13, 2018 Option Exercise$5.046,22431,36912,672May 31, 2018, 04:51 PM
Howard Alvin DVP RegulatoryApr 02, 2018 Sale$5.082341,18942,257Apr 04, 2018, 12:32 PM
Elliott Russell P.VP Drug DevelopmentApr 02, 2018 Sale$5.0814272112,726Apr 04, 2018, 12:30 PM
Domzalski DavidCEOApr 02, 2018 Sale$5.086023,058139,754Apr 04, 2018, 12:28 PM
Elliott Russell P.VP Drug DevelopmentMar 02, 2018 Sale$6.148175,01612,868Mar 06, 2018, 11:50 AM
Domzalski DavidCEOMar 01, 2018 Sale$5.9566393140,356Mar 05, 2018, 11:37 AM
Elliott Russell P.VP Drug DevelopmentJan 02, 2018 Option Exercise$5.985553,3194,935Jan 24, 2018, 08:26 PM
Domzalski DavidCEOJan 02, 2018 Option Exercise$5.982,39714,334140,422Jan 24, 2018, 08:24 PM
Howard Alvin DVP RegulatoryJan 02, 2018 Option Exercise$5.989245,52634,991Jan 24, 2018, 08:22 PM
Eini MeirObserver to the BoardJan 09, 2018 Sale$6.105,00030,5202,727,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 08, 2018 Sale$6.175,00030,8502,732,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 05, 2018 Sale$6.585,00032,8822,737,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 04, 2018 Sale$6.685,00033,4112,742,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 03, 2018 Sale$6.265,00031,3112,747,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 11, 2018 Sale$6.335,00031,6582,717,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 02, 2018 Sale$6.185,00030,9032,752,781Jan 18, 2018, 05:10 PM
Eini MeirObserver to the BoardJan 10, 2018 Sale$6.055,00030,2272,722,781Jan 18, 2018, 05:10 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Domzalski DavidCEO03/02/202012,598
Wiley Matthew T.Chief Commercial Officer03/02/20205,336
Harsch MutyaCLO and General Counsel03/02/20204,715
Wiley Matthew T.Chief Commercial Officer12/31/20198,200
Stuart IainChief Scientific Officer12/31/20191,686
Harsch MutyaCLO and General Counsel12/31/20192,027
Domzalski DavidCEO12/31/20199,023
Domzalski DavidCEO11/29/201921,249
Wiley Matthew T.Chief Commercial Officer11/29/201921,249
Harsch MutyaCLO and General Counsel11/29/20199,249
Hirsch StanleyDirector11/04/201920,150
Hirsch StanleyDirector10/15/201955,800
Stuart IainChief Scientific Officer09/30/20192,066
Harsch MutyaCLO and General Counsel09/30/20191,421
Domzalski DavidCEO09/30/20196,926
Hadar IlanCFO & Country Manager09/10/2019120,375
Hadar IlanCFO & Country Manager09/09/201932,991
KAZANCHYAN ANNADirector08/26/201923,050
Hirsch StanleyDirector08/13/201937,200
KAZANCHYAN ANNADirector07/15/20191,866
Harsch MutyaCLO and General Counsel07/01/20191,502
Domzalski DavidCEO07/01/20197,884
Stuart IainChief Scientific Officer07/01/20192,235
KAZANCHYAN ANNADirector05/20/201927,666
Harsch MutyaCLO and General Counsel04/01/20199,446
Domzalski DavidCEO04/01/201919,110
Stuart IainChief Scientific Officer04/01/20196,360
Wiley Matthew T.Chief Commercial Officer03/05/201950,534
Schwartz AharonDirector11/28/201847,373
Schwartz AharonDirector11/27/2018195,800
Schwartz AharonDirector11/26/2018194,600
Domzalski DavidCEO12/03/2018275
Domzalski DavidCEO11/19/201819,640
Howard Alvin DVP Regulatory11/19/201813,163
Stuart IainSVP R&D11/08/20183,128
Domzalski DavidCEO11/08/20189,444
Howard Alvin DVP Regulatory10/01/20181,360
Elliott Russell P.VP Drug Development10/01/2018825
Domzalski DavidCEO10/01/20183,492
Domzalski DavidCEO09/04/2018380
Domzalski DavidCEO08/08/201846,792
Stuart IainSVP R&D08/08/201815,421
Domzalski DavidCEO07/02/20183,070
Howard Alvin DVP Regulatory07/02/20181,193
Elliott Russell P.VP Drug Development07/02/2018724
Domzalski DavidCEO06/01/2018352
Hirsch StanleyDirector05/13/201831,369
Hirsch StanleyDirector05/13/201831,369
Howard Alvin DVP Regulatory04/02/20181,189
Elliott Russell P.VP Drug Development04/02/2018721
Domzalski DavidCEO04/02/20183,058
Elliott Russell P.VP Drug Development03/02/20185,016
Domzalski DavidCEO03/01/2018393
Elliott Russell P.VP Drug Development01/02/20183,319
Domzalski DavidCEO01/02/201814,334
Howard Alvin DVP Regulatory01/02/20185,526
Eini MeirObserver to the Board01/09/201830,520
Eini MeirObserver to the Board01/08/201830,850
Eini MeirObserver to the Board01/05/201832,882
Eini MeirObserver to the Board01/04/201833,411
Eini MeirObserver to the Board01/03/201831,311
Eini MeirObserver to the Board01/11/201831,658
Eini MeirObserver to the Board01/02/201830,903
Eini MeirObserver to the Board01/10/201830,227
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR FOAMIX PHARMACEUTICALS LTD.
LOADING...